Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Lavipharm S.A. is a company that specializes in the comprehensive lifecycle of pharmaceutical, dermocosmetic, and general healthcare products, from initial research and development to manufacturing, importation, marketing, and distribution. Its operations span both the Greek domestic market and international territories. The company's diverse pharmaceutical offerings cater to numerous therapeutic areas, including cardiology, chronic pain management, oncology, central nervous system disorders, general medicine, gastrointestinal health, and urology. In addition to prescription medications, Lavipharm provides a range of over-the-counter (OTC) drugs such as antiseptics, analgesics, and anti-lice treatments, alongside various skincare solutions. This enterprise, headquartered in Paiania, Greece, was established in 1911.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is reasonably priced on P/E, 'expensive' on EV